Share this page
Imperial Innovations Group portfolio company Circassia, a specialty biopharmaceutical company focused on allergy, has today announced the publication of positive phase II results of its ToleroMune cat allergy treatment in the Journal of Allergy and Clinical Immunology.
The results show that cat allergy patients who received four doses of the ToleroMune treatment over 12 weeks maintained a significantly greater improvement in symptoms (when compared to placebo) one year after the study commenced.
Steve Harris, CEO of Circassia, commented:
“These results are extremely encouraging, as they suggest our novel ToleroMune® cat allergy therapy has the potential to modify the underlying allergic disease, and thereby offer patients ongoing symptom improvement after just a short course of treatment.
"The peer-reviewed publication of these clinical results in the leading journal in the allergy field, the Journal of Allergy and Clinical Immunology, is an important achievement for Circassia as we rapidly progress our ToleroMune® treatment into phase III development.”